Accessibility Menu
Next Science logo

Next Science(ASX) NXS

This security has been delisted. This page is retained for historical reference.

Next Science last closing stock price
MetricPriceDate
Last closeAUD 0.152025-12-31
Next Science stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.152025-12-24
1 month+0%AUD 0.152025-12-01
3 month-3.33%AUD 0.152025-10-02
Year to date+26.09%AUD 0.122024-12-31
1 year+26.09%AUD 0.122024-12-31
3 year-78.83%AUD 0.692022-12-30
5 year-88.4%AUD 1.252020-12-31
Since inception-89.26%AUD 1.352019-04-18

NXS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

NXS Financials

Key Financial Metrics (TTM)

Gross Margin

80.83%

Operating Margin

-45.16%

Net Income Margin

-46.40%

Return on Equity

-130.18%

Return on Capital

-173.60%

Return on Assets

-114.89%

Earnings Yield

N/A

Dividend Yield

100.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$32.01M

Operating Income

-$16.32M

EBITDA

-$15.15M

Operating Cash Flow

-$17.19M

Capital Expenditure

-$451.50K

Free Cash Flow

-$17.64M

Cash & ST Invst.

$971.24K

Total Debt

$5.30M

Next Science Performance Analysis

Next Science annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 11,921,023N/A
20222022-12-31USD 16,895,83341.7%
20232023-12-31USD 33,414,36697.8%
20242024-12-31USD 34,591,1143.5%
Next Science sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3126.6%
Q22024-06-30-10.8%
Q42024-12-313.1%
Q22025-06-30-54.7%
Next Science annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.06N/A
20222022-12-31USD -0.0937.3%
20232023-12-31USD -0.1020.5%
20242024-12-31USD -0.06-47.5%
Next Science sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3161.7%
Q22024-06-30-98.7%
Q42024-12-3146.0%
Q22025-06-3050.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$5.25M

-47.2%

Gross Profit

$4.36M

-29.5%

Gross Margin

83.16%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$2.34M

+72.3%

EBITDA

-$2.05M

+73.1%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$971.24K

-72.4%

Total Debt

$5.30M

-26.9%

Accounts Receivable

$4.53M

+76.4%

Inventory

$615.43K

-40.7%

Long Term Debt

$5.04M

-30.6%

Short Term Debt

$266.52K

-0.3%

Return on Assets

-1.15%

N/A

Return on Invested Capital

-1.72%

N/A

Free Cash Flow

-$1.39M

+83.0%

Operating Cash Flow

-$1.39M

+81.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIT.AXVitura Health Limited
A$0.02+0.00%
LGP.AXLittle Green Pharma Ltd
A$0.08+1.33%
ADO.AXAnteoTech Limited
A$0.02-5.26%
EYE.AXNova Eye Medical Limited
A$0.15-3.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.